PL3793534T3 - Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego - Google Patents

Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego

Info

Publication number
PL3793534T3
PL3793534T3 PL19729181.8T PL19729181T PL3793534T3 PL 3793534 T3 PL3793534 T3 PL 3793534T3 PL 19729181 T PL19729181 T PL 19729181T PL 3793534 T3 PL3793534 T3 PL 3793534T3
Authority
PL
Poland
Prior art keywords
delivery
active ingredients
gastrointestinal tract
oral tablet
oral
Prior art date
Application number
PL19729181.8T
Other languages
English (en)
Inventor
Helle Wittorff
Original Assignee
Fertin Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fertin Pharma A/S filed Critical Fertin Pharma A/S
Publication of PL3793534T3 publication Critical patent/PL3793534T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19729181.8T 2018-05-17 2019-05-15 Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego PL3793534T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/982,593 US20190350858A1 (en) 2018-05-17 2018-05-17 Oral tablet for delivery of active ingredients to the gastrointestinal tract
PCT/DK2019/050159 WO2019219149A1 (en) 2018-05-17 2019-05-15 An oral tablet for delivery of active ingredients to the gastrointestinal tract

Publications (1)

Publication Number Publication Date
PL3793534T3 true PL3793534T3 (pl) 2023-06-05

Family

ID=66793737

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19729181.8T PL3793534T3 (pl) 2018-05-17 2019-05-15 Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego

Country Status (8)

Country Link
US (2) US20190350858A1 (pl)
EP (1) EP3793534B1 (pl)
CN (1) CN112218624A (pl)
CA (1) CA3098086C (pl)
DK (1) DK3793534T3 (pl)
ES (1) ES2943835T3 (pl)
PL (1) PL3793534T3 (pl)
WO (1) WO2019219149A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096894B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
US11096896B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
AU2021268062B2 (en) * 2020-05-08 2024-08-15 Fertin Pharma A/S Flowpack for oral delivery of active ingredients
CN112220756B (zh) * 2020-10-16 2023-06-13 重庆市义力医药科技有限公司 一种尼古丁颗粒组合物及其制备方法
KR20230121888A (ko) * 2020-12-19 2023-08-21 아바카 파마 프라이빗 리미티드 펙소페나딘, 파모티딘 및 멜라토닌을 포함하는 약학조성물
WO2022157564A1 (en) * 2021-01-23 2022-07-28 Cellix Bio Private Limited A pharmaceutical composition comprising famotidine, lidocaine and melatonin
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product
WO2023187664A1 (en) * 2022-03-30 2023-10-05 Avaca Pharma Private Limited A pharmaceutical composition for the treatment of immune system mediated diseases
PL249823B1 (pl) * 2023-12-04 2026-06-29 Politechnika Slaska Im Wincent Sposób otrzymywania koniugatów jonowych do współdostarczania leków o aktywności przeciwbakteryjnej oraz ich zastosowanie
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1080024A (en) 1975-12-24 1980-06-24 Leonard Spooner Confection containing xylitol
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4820506A (en) 1987-05-01 1989-04-11 Research Foundation, State University Of New York Salivary stimulant
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
GB9100009D0 (en) 1991-01-02 1991-02-20 Cerestar Holding Bv Erythritol compositions
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
TW469135B (en) 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
RU2189227C2 (ru) 1996-07-12 2002-09-20 Дайити Фармасьютикал Ко., Лтд. Быстро распадающиеся прессованные в формах материалы и способ их получения
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9716432D0 (en) 1997-08-05 1997-10-08 Cerestar Holding Bv Tableting of erythritol
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US5874068A (en) 1997-12-08 1999-02-23 Warner-Lambert Company Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts
JP2001526212A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
EP1369109A1 (en) 2001-03-06 2003-12-10 Kyowa Hakko Kogyo Co., Ltd. Preparations quickly disintegrating in oral cavity
SE0102197D0 (sv) 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
US20030215502A1 (en) 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
MXPA05007346A (es) 2003-02-04 2005-09-30 Gumlink As Tableta de goma de mascar comprimida.
US7223072B2 (en) 2004-01-27 2007-05-29 Honeywell International, Inc. Gas turbine engine including airfoils having an improved airfoil film cooling configuration and method therefor
WO2006063189A2 (en) 2004-12-10 2006-06-15 Novartis Ag Multi-layered chewing gum tablet with quick disintegration layer
EP1863466B1 (en) 2005-03-03 2017-08-09 Takasago International Corporation (USA) Synergistic salivation components
ATE462416T1 (de) * 2006-08-04 2010-04-15 Ethypharm Sa Mehrschichtige im mund zerfallende tablette
WO2009007768A1 (en) 2007-07-06 2009-01-15 Gumlink A/S Compressed tablet comprising polyol
WO2009016133A1 (en) 2007-07-27 2009-02-05 Cargill, Incorporated Micronization of polyols
WO2009080023A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising peptide
ES2377869T3 (es) 2008-09-04 2012-04-02 Cargill, Incorporated Fabricación de comprimidos de eritritol
AU2010223105B2 (en) 2009-03-09 2016-05-12 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
US9591852B2 (en) 2009-11-23 2017-03-14 Mcneil-Ppc, Inc. Biofilm disruptive compositions
US8658139B1 (en) 2010-02-27 2014-02-25 Squigle, Inc. Prevention and treatment of oral diseases
JP6521564B2 (ja) 2010-12-22 2019-05-29 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 速崩性の固体被覆剤形
WO2013091631A1 (en) * 2011-12-22 2013-06-27 Fertin Pharma A/S Method of releasing nicotine from chewing gum
JP6040218B2 (ja) 2012-02-23 2016-12-07 フロイント産業株式会社 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
WO2013171164A1 (en) * 2012-05-14 2013-11-21 EJP Pharmaceutical ApS Compositions and formulations for the treatment of halitosis
WO2014185792A1 (en) 2013-05-17 2014-11-20 Ozospa Holdings Limited Oral healthcare product
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
WO2016061486A1 (en) 2014-10-16 2016-04-21 Cargill, Incorporated Process for preparing a directly compressible erythritol & uses thereof
AU2015346374A1 (en) 2014-11-11 2017-04-27 Johnson & Johnson Consumer Inc. Amino acid derivatives and their uses
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
JP6840849B2 (ja) 2016-11-18 2021-03-10 フェルティン ファルマ アー／エス 別個の結合剤及びエリスリトールを含む錠剤
US11351103B2 (en) 2016-11-18 2022-06-07 Johnson & Johnson Consumer Inc. Method of providing oral care benefits
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
EP3854383A1 (en) * 2016-11-18 2021-07-28 Fertin Pharma A/S Oral delivery vehicle

Also Published As

Publication number Publication date
EP3793534A1 (en) 2021-03-24
CN112218624A (zh) 2021-01-12
CA3098086A1 (en) 2019-11-21
DK3793534T3 (da) 2023-05-01
ES2943835T3 (es) 2023-06-16
US11260030B2 (en) 2022-03-01
US20210299052A1 (en) 2021-09-30
WO2019219149A1 (en) 2019-11-21
US20190350858A1 (en) 2019-11-21
CA3098086C (en) 2023-10-17
EP3793534B1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
IL275220A (en) Oral administration of active drug substances
IL279464A (en) Pharmaceutical formulation of odevixibat
DK3793534T3 (da) Oral tablet til levering af aktive ingredienser til mavetarmkanalen
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
ZA201908454B (en) Solid preparation of cariprazine for oral administration
IL273740A (en) Oral pharmaceutical formulation containing bacteria
IL277443A (en) A system for delivering a fluid and ingestible drug into the user's digestive system
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
IL264880A (en) Preparations for oral administration of active substances
SG11202010124SA (en) Stable pharmaceutical formulation
EA036036B1 (ru) Композиции, содержащие циклоспорин
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
EP3781135A4 (en) Solid oral pharmaceutical compositions comprising sitagliptin
GB202103724D0 (en) Pharmaceuticals solution for oral dosage
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
EP3346996A4 (en) ORAL PHARMACEUTICAL PHARMACEUTICAL FORM OF BUDESONID
PT3318259T (pt) Composição farmacêutica estável para administração oral
SG11202008768VA (en) Pharmaceutical composition comprising brexpiprazole
HUE064843T2 (hu) Orális oldat kiszerelés
PL3326619T3 (pl) Stałe doustne kompozycje farmaceutyczne zawierające tenofowir i emtrycytabinę
SG11202010792TA (en) Improved pharmaceutical formulations
GB201721604D0 (en) An oral liquid pharmaceutical composition of lamotrigine`
PL3880171T3 (pl) Doustny preparat farmaceutyczny zawierający ibuprofen
SG11202101547WA (en) Pharmaceutical composition for oral administration